Italfarmaco S.p.A.

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), Vertex Pharmaceuticals’ next generation treatment for cystic fibrosis (CF) is one of six orphan products that the European Medicines Agency backed for

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

Eli Lilly and Italfarmaco were due this week to appear before the European Medicines Agency’s human medicines committee, the CHMP, for oral explanations as to why their respective drugs, donanemab and

An Indian court has issued far-reaching directions to the government apparatus and pharma, among other stakeholders, as part of efforts to ensure patients suffering from rare diseases get timely acces